Drugs in MeSH Category Angiogenesis Inhibitors

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785-001	Jul 16, 1998		RX	Yes	No
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785-004	Jan 10, 2007		RX	Yes	No
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785-003	Jan 17, 2003		RX	Yes	Yes
Natco	THALIDOMIDE	thalidomide	CAPSULE;ORAL	213267-001	Apr 27, 2023		DISCN	No	No
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785-002	Jan 17, 2003		RX	Yes	No

Angiogenesis Inhibitors Market Analysis and Financial Projection

The angiogenesis inhibitors market is experiencing robust growth driven by rising cancer prevalence and advancements in targeted therapies. With a projected CAGR of 12.9% (2025–2032), the market is propelled by increased R&D investments and the development of combination therapies[1][6]. VEGF inhibitors dominate this space, with their market expected to reach $19.35 billion by 2030[4]. Key players like Roche (Avastin), Pfizer, and Novartis leverage strong pipelines and strategic partnerships to maintain market leadership, while biosimilars gradually emerge post-patent expirations[1][13].

Market Dynamics

• Growth Drivers:

  • Rising global cancer incidence, particularly breast, lung, and colorectal cancers.
  • Aging populations and demand for minimally invasive therapies[1][6].
  • Innovations in precision medicine and combination regimens (e.g., angiogenesis inhibitors with immunotherapy)[1][3].

• Regional Insights:

  • North America leads with ~45% market share due to advanced healthcare infrastructure[1].
  • Asia-Pacific shows the fastest growth (~20% share), driven by improving healthcare access and economic expansion in China and India[1][6].

• Competitive Landscape:

  • Roche’s Avastin generated $6.6 billion annually before biosimilar entry[13].
  • Emerging biosimilars face delays due to patent litigations and secondary patents on formulations or dosing[5][13].

Patent Landscape

1. Core Patents:

   • US9642865B2 covers methods of inhibiting angiogenesis using specific compounds[2].
   • US6028061A protects glycosaminoglycan-based inhibitors[7].
   • KR19990082523A claims N-(3,4-dimethoxycinnamoyl) anthranilic acid for diabetic retinopathy and arthritis[12].

2. Patent Strategies:

   • Originators file secondary patents (e.g., new formulations, delivery methods) to extend exclusivity. For example, Inhibitor Therapeutics licensed JHU’s patent (US8,980,930) for itraconazole as an angiogenesis inhibitor[9].
   • Biosimilar developers like Amgen navigate litigation risks, as seen with Roche’s Avastin patents in Europe[13].

3. Biosimilar Challenges:

   • Legal Hurdles: Over 1,300 patent families target immune checkpoints (e.g., PD-1/CTLA-4), creating dense IP landscapes[11].
   • Market Entry Delays: Biosimilars often launch only after resolving disputes, as seen with Amgen’s ABP 215, which awaited Roche’s EU patent expiry in 2022[13].

Future Outlook

• Innovation Trends: Focus on dual-target therapies (e.g., VEGF/Dll4 inhibition) and repurposing existing drugs (e.g., itraconazole)[3][9].
• Regulatory and Economic Factors: Expedited approvals for oncology drugs and cost pressures from biosimilars will shape pricing strategies[5][6].

“The combined blockade of VEGF and Dll4 results in the inhibition of tumor progression and angiogenesis throughout the tumor.”
—Angiogenesis mechanism study[3]

As the market evolves, companies balancing patent agility with clinical innovation will dominate, while biosimilars gradually democratize access to life-saving therapies.

References

1. https://github.com/shefikagbons/Market-Research-Report-List-1/blob/main/angiogenesis-inhibitors-market.md
2. https://patents.google.com/patent/US9642865B2/en
3. https://en.wikipedia.org/wiki/Angiogenesis
4. https://www.mordorintelligence.com/industry-reports/vascular-endothelial-growth-factors-inhibitors-market
5. https://pmc.ncbi.nlm.nih.gov/articles/PMC7188399/
6. https://www.databridgemarketresearch.com/reports/global-angiogenesis-inhibitors-market
7. https://patents.google.com/patent/US6028061
8. https://en.wikipedia.org/wiki/List_of_MeSH_codes_(D27)
9. https://www.biospace.com/inhibitor-therapeutics-inc-exclusive-license-with-johns-hopkins-university
10. https://patents.justia.com/patent/20150320782
11. https://ipwatchdog.com/2017/08/10/immunotherapy-patent-landscape-patent-claims-immunotherapeutic-inventions/id=86634/
12. https://patents.google.com/patent/KR19990082523A/en
13. https://www.labiotech.eu/trends-news/roches-patent-halts-an-amgen-biosimilar-debut/